Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melflufen and Dexamethasone in Relapsed/Refractory AL Amyloidosis
NCT04115956Phase 1Terminated
- Sponsor
- Oncopeptides AB
- Start
- Aug 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 9
01
Overview
Phase 1, open-label, single-arm trial of melphalan flufenamide in amyloid light chain amyloidosis, sponsored by Oncopeptides AB. Primary endpoints: Safety and Tolerability at 8 months, Recommended Phase 2 Dose at 8 months and 1 more. Started Aug 2020; status: terminated.
02
Drugs
melphalan flufenamide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04115956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115956.